uniQure (NASDAQ:QURE) Stock Price Passes Below 200-Day Moving Average of $6.06

uniQure (NASDAQ:QURE)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.06 and traded as low as $4.66. uniQure shares last traded at $4.71, with a volume of 440,845 shares changing hands.

Analyst Ratings Changes

Several research firms have recently commented on QURE. Mizuho lowered their price target on shares of uniQure from $10.00 to $7.00 and set a “neutral” rating on the stock in a report on Monday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $28.00 price objective on shares of uniQure in a report on Tuesday, January 16th. The Goldman Sachs Group cut shares of uniQure from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $63.00 to $8.00 in a report on Thursday, February 29th. StockNews.com upgraded shares of uniQure to a “sell” rating in a report on Friday, March 1st. Finally, HC Wainwright decreased their price objective on shares of uniQure from $30.00 to $25.00 and set a “buy” rating for the company in a report on Friday, March 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

uniQure Price Performance

The stock’s 50-day moving average price is $5.36 and its 200 day moving average price is $6.05. The firm has a market cap of $223.41 million, a price-to-earnings ratio of -0.72 and a beta of 0.95. The company has a quick ratio of 8.68, a current ratio of 8.85 and a debt-to-equity ratio of 0.49.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($1.53) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.01. The business had revenue of $6.69 million during the quarter, compared to analyst estimates of $3.20 million. uniQure had a negative net margin of 1,947.09% and a negative return on equity of 99.31%. Equities research analysts predict that uniQure will post -4.49 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Christian Klemt sold 15,906 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.38, for a total value of $101,480.28. Following the completion of the transaction, the chief financial officer now owns 116,948 shares of the company’s stock, valued at $746,128.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Matthew C. Kapusta sold 27,904 shares of the stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the transaction, the chief executive officer now owns 440,839 shares of the company’s stock, valued at $2,799,327.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christian Klemt sold 15,906 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $6.38, for a total transaction of $101,480.28. Following the completion of the transaction, the chief financial officer now directly owns 116,948 shares of the company’s stock, valued at approximately $746,128.24. The disclosure for this sale can be found here. Insiders sold 53,265 shares of company stock valued at $339,845 over the last quarter. Corporate insiders own 4.05% of the company’s stock.

Institutional Trading of uniQure

Several large investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in uniQure by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 962,796 shares of the biotechnology company’s stock worth $6,518,000 after buying an additional 9,360 shares during the last quarter. Virtu Financial LLC bought a new stake in uniQure during the fourth quarter worth about $195,000. Virtus ETF Advisers LLC grew its stake in uniQure by 123.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 11,430 shares of the biotechnology company’s stock worth $77,000 after buying an additional 6,326 shares during the last quarter. Bridger Management LLC grew its stake in uniQure by 2,917.3% during the fourth quarter. Bridger Management LLC now owns 362,349 shares of the biotechnology company’s stock worth $2,453,000 after buying an additional 350,340 shares during the last quarter. Finally, Brevan Howard Capital Management LP bought a new stake in uniQure during the fourth quarter worth about $158,000. 78.83% of the stock is owned by institutional investors.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.